What good Wegovy care actually involves

What the STEP 1 trial tells us about the care patients actually received

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks. Every participant received regular contact from their study team alongside the medicine. That context matters because the headline figure (roughly 15% average weight reduction at 2.4mg) reflects a supported population, not people injecting in isolation.

What structured support provided in that trial was relatively straightforward: someone checking in on tolerability at each dose step, prompting around diet and activity, and catching problems early. Those aren't complicated interventions. They are, though, consistently absent when people source medicine through unmonitored channels.

The dose journey itself creates natural review points, and if you want a clear breakdown of what each dose level involves and how the steps progress, that can help you understand what to expect at each stage. Semaglutide starts at 0.25mg and steps up through 0.5mg, 1.0mg, 1.7mg, and 2.4mg, with roughly four weeks at each level. A prescriber who is genuinely engaged can adjust that pace based on how a patient is actually coping — slowing a step if nausea is difficult, or holding a dose rather than pushing to the next one.

Side effects that good care anticipates rather than leaves people to discover alone

Gastrointestinal symptoms (nausea, loose stools, constipation, reflux, bloating) are the most commonly reported effects of semaglutide, and they cluster around the early weeks of each new dose. Most settle within a fortnight. That pattern is predictable enough that prescribers can brief patients on it in advance, which substantially reduces the anxiety that sends people to search engines at 11pm wondering whether to stop.

There are symptoms that do need prompt attention. The MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as an infrequent but serious risk with GLP-1 medicines: severe, persistent stomach pain that may travel through to the back, with or without vomiting, warrants urgent medical assessment rather than a wait-and-see approach. Gallbladder problems and significant dehydration from prolonged vomiting or diarrhoea also need clinical review rather than self-management. People who are scared to start Wegovy because of these possibilities often feel more settled once they know what the actual warning signs are versus normal adjustment symptoms.

Side effects can also be reported directly to the MHRA through the Yellow Card scheme, which continues to build the real-world safety picture beyond trial data.

Nutrition, activity and the things that amplify (or undermine) the treatment

Appetite suppression on semaglutide is real and often significant. That's the point. But when overall intake drops sharply, protein is frequently the first casualty, people stop feeling hungry for chicken and fish before they stop wanting bread. Muscle loss during rapid weight reduction is a genuine concern, and adequate protein intake is one of the practical levers that mitigates it. Some people find adjusting their carbohydrate balance helpful, though there is no single dietary prescription that applies to everyone on this treatment.

Hydration matters more than it sounds. Nausea can make drinking feel unappealing; reduced appetite applies to fluids as much as food; and dehydration amplifies GI symptoms. A prescriber who asks about these things at follow-up is doing clinical work, not making conversation.

Physical activity alongside treatment is consistently associated with better outcomes. The aim isn't high-intensity exercise from week one; it's building habits that are sustainable once the medicine has helped reshape appetite and energy. The NHS healthy weight guidance sets a sensible baseline, and a prescriber can point you toward appropriate resources based on your starting point.

What ongoing care looks like at a private pharmacy, and when to ask for it

NHS access to Wegovy is limited to specialist weight management services under NICE guidance, and waiting lists for those services are often long. For people who are clinically suitable but either don't qualify at this stage or can't wait, a regulated private pharmacy is the legal alternative, as long as every prescription involves a genuine clinical assessment, not a rubber-stamped order form.

At nume, our clinical model is built around a GPhC-registered Independent Prescriber personally reviewing every consultation and every repeat request. There are no auto-renewals. If you're curious about what our prescribers look at across a full weight-loss programme, the treatment overview sets that out clearly. For those considering how cost fits into longer-term treatment planning, the Wegovy pricing page explains what a transparent private prescription actually covers.

A Monday order placed before 12pm means your prescription is reviewed the same day and, once approved, your pen ships that afternoon. If a bank holiday or a holiday period affects your timing, it's worth planning a few days ahead so you're not caught without your next pen. That kind of logistical continuity is part of care too, running out mid-titration and skipping a dose is something to avoid where possible, and your prescriber can advise if it happens.

If you'd like to discuss what an appropriate care plan looks like for your specific situation, speak to our prescribers through a free consultation.